Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 175 results
February 2018
-
Media ReleaseNovartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasisMajority of patients with scalp psoriasis on Cosentyx® (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life[1] Scalp psoriasis affects 60 million…
-
Media ReleaseNovartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasisUS label updated to include Cosentyx® (secukinumab) data in moderate-to-severe scalp psoriasis[1] - one of the difficult-to-treat types of psoriasis[2] Approximately half of all 125 million…
January 2018
-
Media ReleaseSandoz announces exclusive global collaboration with Biocon on next-generation biosimilarsCollaboration aims to help patients worldwide gain access to a range of high-quality, affordable immunology and oncology biologics Partnership will be an important part of Sandoz and Biocon…
-
Media ReleaseNovartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCLFiling acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy EMA granted…
-
Media ReleaseNovartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patientsResults from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara®* (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks[1]…
-
Media ReleaseSandoz regulatory submission for proposed biosimilar adalimumab accepted by FDAAdalimumab is an anti-TNF medicine used to treat a range of immunological diseases[1] The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab…
-
Media ReleaseNovartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS)[1] EXCEED is the first head-to-head superiority trial…
November 2017
-
Media ReleaseNovartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patientsUnique Cosentyx® (secukinumab) data reinforce treatment option for up to 90% of psoriasis patients who may develop nail or palmoplantar psoriasis[1]-[4] Cosentyx results represent the first data…
-
Media ReleaseNew data reinforces clinical basis for switching to Sandoz biosimilar medicinesSandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar…
-
Media ReleaseNovartis highlights its differentiated late stage pipeline at the R&D update and investor eventRTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD AMG 334 has a…
-
Media ReleaseNovartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCLApplication follows sBLA submission to the FDA for r/r DLBCL which marked second US application for first-ever FDA approved CAR-T therapy Building on the US r/r B-cell ALL experience, Novartis…
Pagination
- ‹ Previous page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- …
- 15
- › Next page